AMSBIO launches research tool suite for checkpoint inhibitors

By Phil Taylor

- Last updated on GMT

Images: iStock/Matej Kastelic
Images: iStock/Matej Kastelic

Related tags: Cancer

Anglo-American life science firm AMS Biotechnology has launched new cell lines to help companies researching the PD-1/PD-L1 pathway, one of the hottest areas of immuno-oncology research.

PD-1 (programmed cell death-1) is a receptor expressed on activated T cells and - when bound to ligands PD-L1 or PD-L2 has been shown to down-regulate immune responses. It is known that many cancer cells expressed PD-L1 and PD-L2 and this helps them evade destruction by the immune system.

There are already three 'checkpoint inhibitor' drugs on the market which target the pathway - Merck & Co's Keytruda (pembrolizumab), Bristol-Myers Squibb's Opdivo (nivolumab) and Roche's Tecentriq (atezolizumab) - and there are several other candidates in trials including AstraZeneca's durvalumab and Pfizer/Merck KGaA avelumab.

AMSBIO says the two new cell lines will help companies discover and develop new compounds that target the PD-1/PD-L1 pathway. The first is a PD-1/NFAT Reporter - Jurkat cell line that can be used to screen for activators or inhibitors of PD-1 signalling as well as for studying the biological activity of PD-1 and its interactions with ligands.

An accompanying TCR activator/PD-L1 - Chinese hamster ovary (CHO) cell line can also be used for screening for activators or inhibitors of PD-1 signalling, as well as screening PD-L1 antibodies for their binding affinity to the receptor.

"Activation of the immune system involves a number of checkpoints in order to ensure proper activation,"​ said ASMBIO.

"Given its diverse function and the fact that the immune system plays a role in virtually all human diseases, immunotherapy has become an important approach for the treatment of numerous diseases,"​ it added, noting that PD-1 and PD-L1 may also be potential targets in multiple sclerosis, arthritis, lupus, and type I diabetes.

Collectively, the PD-1/PD-L1 inhibitors and drugs targeting other immune checkpoints such as CTLA-4 have been tipped by market research firm Visiongain to grow into a therapeutic category worth $16.5bn or more by 2020 in cancer alone, thanks to exceptional, durable efficacy across a number of tumour types.

The PD-1/PD-L1 inhibitors are predicted to account for the bulk of that market, it said.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars